SCHEDULE: T. Rowe Price Discloses 3.7% Stake in Avanos Medical

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 3.7% of Avanos Medical Inc.'s common stock as of April 30, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed an amendment to its Schedule 13G filing.
• The filing indicates that as of April 30, 2026, T. Rowe Price Investment Management, Inc. beneficially owns 1,703,510 shares of Avanos Medical Inc. common stock.
• This represents 3.7% of the class of securities.
• The reporting entity has sole voting power over 1,680,454 shares and sole dispositive power over 1,703,510 shares.
• There is no shared voting or dispositive power reported.
• T. Rowe Price Investment Management, Inc. is registered as an investment adviser and is filing under Rule 13d-1(b).
• The company certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant institutional investor's stake without providing performance data or explicit positive/negative commentary on the company's operations.

Positives

• T. Rowe Price Investment Management, Inc., a significant investment manager, has taken a notable position in Avanos Medical Inc., potentially signaling confidence in the company's future prospects.
• The filing confirms a substantial beneficial ownership stake of 3.7%, indicating active investment management.

Negatives

• The filing does not contain any negative financial results or operational challenges for Avanos Medical Inc.

Risks

• The filing does not explicitly mention any risks related to Avanos Medical Inc.'s operations or financial health.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Avanos Medical Inc.'s future performance. It solely reports on current beneficial ownership.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• Certification that securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by major investment firms like T. Rowe Price often indicate a significant investment thesis, potentially influencing market perception and other investors' decisions regarding companies in the medical technology sector.

Stakeholder Impact

• Shareholders: The increased institutional interest from a firm like T. Rowe Price may positively influence investor sentiment and potentially the stock price.
• Management: The filing confirms a significant investor's stake, which may lead to increased scrutiny or engagement from T. Rowe Price.
• Employees: No direct impact mentioned.

Next Steps

• No specific next steps for Avanos Medical Inc. are mentioned in this filing.
• T. Rowe Price Investment Management, Inc. will continue to hold or manage its beneficial ownership of Avanos Medical Inc. shares.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not contain operational or financial performance data for Avanos Medical Inc. While the significant stake by T. Rowe Price is noteworthy, it does not provide sufficient information to warrant a buy or sell recommendation. A 'hold' is appropriate pending further performance-related disclosures.

Keywords

Avanos Medical Inc, Schedule 13G, T. Rowe Price Investment Management, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Securities Exchange Act